Odyssey Therapeutics, Inc. (ODTX)
$18.26-3.89%Close
SELL
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $552M
- Beta
- 1.43
- P/E (TTM)
- -7.11
- Short % float
- 12.14%
- Days to cover
- 5.6
- SI change
- +40.6%
- 1W
- -12.38%
- 1M
- -25.86%
- vs SPY 1W
- -12.80%
- vs SPY 1M
- -27.92%
Industry peers
FMP comparable companies · ranked by market cap
- PTGXSELLProtagonist Therapeutics, Inc.$9.2BRECOVERYQ 32$143.73+0.80%
- SYRESELLSpyre Therapeutics, Inc.$7.4BCRISISQ 10$85.69+0.25%
- ORKASELLOruka Therapeutics, Inc.$5.0BCRISISQ -3$82.11-2.14%
- ANABSELLAnaptysBio, Inc.$1.4BCRISISQ 25$45.95+0.20%
- ALMSSELLAlumis Inc.$884MCRISISQ 1$7.16-1.40%
- ACRSSELLAclaris Therapeutics, Inc.$535MCRISISQ 9$3.83-6.01%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on ODTX?
- LOPJLB’s latest quantitative signal on Odyssey Therapeutics, Inc. (ODTX) is SELL. Signals are updated daily.
- What market regime is ODTX in?
- LOPJLB classifies each ticker into BULL, RECOVERY, BEAR, or CRISIS regimes using a Hidden Markov Model.
- What does Odyssey Therapeutics, Inc. (ODTX) do?
- Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is…